Cargando…
Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder
AIM: To compare atomoxetine (ATX) length of therapy (LoT) among adults with ADHD who reached the recommended dose of 80 mg/day (ATX ≥ 80) versus those who did not (ATX < 80) analyzed separately in patients prescribed ATX as monotherapy (mono) and in combination with other ADHD medications (combo)...
Autores principales: | Clemow, David B., Nyhuis, Allen W., Robinson, Rebecca L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129573/ https://www.ncbi.nlm.nih.gov/pubmed/27476490 http://dx.doi.org/10.1111/cns.12595 |
Ejemplares similares
-
Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder
por: Kabul, Samaneh, et al.
Publicado: (2015) -
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
por: Clemow, David B, et al.
Publicado: (2017) -
Effect of Atomoxetine on Hyperactivity in an Animal Model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Moon, Su Jin, et al.
Publicado: (2014) -
Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
por: Nagai, Tsutomu, et al.
Publicado: (2022) -
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)